The Pfizer CEO was unaware that a fourth dose of the Covit-19 vaccine was needed

On September 29, 2021, a nurse at the Pfizer-Bioentech Vaccine Clinic in Southfield, Michigan, USA, fills syringes for patients receiving a stimulant vaccine against the corona virus (COVID-19). REUTERS / Emily Elconin

January 10 (Reuters) – Pfizer Inc. (PFE.N) CEO Albert Borla said Monday Not sure about the need A fourth dose of the Covit-19 vaccine and a shot aimed at the most contagious Omigron variant Will be ready in March.

Contradictory views with Moderna Inc (MRNA.O) CEO Stephen Pancel said last week that people can Need another shot The performance of boosters in the fall of 2022 is likely to decline over the next few months.

A large omigran-driven spike in the Covit-19 cases forced some countries to look at another booster dose, but early signs suggest that repeated vaccinations may be hard to sell as infected people enter their third epidemic year. read more

Ahead of Pfizer’s presentation at the JPMorgan Healthcare conference, Borla told CNBC, “I do not know if a fourth booster is needed, it is something that needs to be tested.”

Work is underway on a new version of the COVID-19 vaccine that could work against Omigran and other variants, he said.

The US pharmaceutical maker has announced three deals to expand the use of Messenger RNA technology (MRNA) based on its Govit-19 vaccine, which includes a $ 1.35 billion deal with beam editing specialist Beam Therapeutics. (Beam.O).

Pfizer is seeking to improve the development of mRNA-based vaccines and therapies, leading to global efforts to develop a COVID-19 shot against infection.

The company will operate in association with Codex DNA Inc. (DNAY.O) To utilize the proprietary technology of biotechnology that can enable the efficient development of MRNA based vaccines, therapies and other biopharmaceutical products.

It will focus on developing ten vaccines or treatments using the Vancouver-based company’s lipid nanoparticle technology under contract with private biotech Aquitas Therapeutics.

Report by Banvi Satija, Manojna Mattipatla and Mrinalika Roy in Bangalore; Editing by Devika Siamnath and Aditya Soni

Our standards: Thomson Reuters Trust Principles.